BURLINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) — Fractyl Health, Inc. Nasdaq: GUTS (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced it will report financial results for the first quarter 2024 and provide business updates after market close on Monday, May 13, 2024. The Company’s management will host a conference call on the same day beginning at 4:30 p.m. ET.

A live webcast of the conference call can be accessed in the “Events” section of Fractyl’s website at www.ir.fractyl.com. The webcast will be archived and available for replay following the live event.

About Fractyl Health

Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. Fractyl Health is based in Burlington, MA. For more information, visit www.fractyl.com or https://twitter.com/FractylHealth.

Contacts 

Corporate Contact 
Lisa Davidson, Chief Financial Officer 
ir@fractyl.com, 781.902.8800

Media Contact 
Beth Brett, Corporate Communications 
bbrett@fractyl.com, 720.656.6544

Investor Contact
Stephen Jasper Gilmartin Group
stephen@gilmartinir.com, 619.949.3681